Latest news

• Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

  EFS was defined in the study as the time from randomisation to disease progression, the start of a new lymphoma therapy or death from any cause. ... Yescarta is also indicated in the third- or later-line LBCL setting and for the treatment of adult

• Yescarta gains first FDA approval for indolent follicular lymphoma

  follicular lymphoma, becoming the first CAR-T cell therapy approved in this indication. ... Specifically, Yescarta (axicabtagene ciloleucel) has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) – a

• Celgene’s Revlimid scores NICE approval in follicular lymphoma

  lymphoma. Follicular lymphoma is the most common type of low-grade non-Hodgkin’s lymphoma, and despite having a median overall survival rate of over 15 years, patients are prone to ... Lenalidomide is a new type of targeted cancer therapy for people

• EU grants conditional approval to Roche's lymphoma drug Polivy

  The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory  diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL

• Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

  This includes trials of tafasitamab in non-Hodgkins lymphoma, chronic lymphocytic leukaemia (CLL), relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) and frontline DLBCL. ... beyond DLBCL, such as follicular lymphoma (FL), marginal zone